AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 8.5% in March

AngioDynamics, Inc. (NASDAQ:ANGO) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 2,250,000 shares, a drop of 8.5% from the March 15th total of 2,460,000 shares. Based on an average daily volume of 575,400 shares, the short-interest ratio is presently 3.9 days.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ANGO shares. Oppenheimer raised shares of AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a report on Friday, April 5th. HC Wainwright cut their target price on shares of AngioDynamics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, January 8th. Finally, Raymond James cut their target price on shares of AngioDynamics from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, January 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

Insider Buying and Selling

In other news, CEO James C. Clemmer purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was acquired at an average cost of $6.70 per share, for a total transaction of $67,000.00. Following the completion of the purchase, the chief executive officer now owns 539,066 shares of the company’s stock, valued at $3,611,742.20. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of AngioDynamics by 6.4% during the fourth quarter. Vanguard Group Inc. now owns 2,268,461 shares of the medical instruments supplier’s stock valued at $17,785,000 after buying an additional 136,323 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in AngioDynamics by 19.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 30,951 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 5,131 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in AngioDynamics by 21.4% during the fourth quarter. Public Employees Retirement System of Ohio now owns 76,539 shares of the medical instruments supplier’s stock worth $600,000 after purchasing an additional 13,500 shares in the last quarter. Barclays PLC raised its holdings in AngioDynamics by 131.3% during the fourth quarter. Barclays PLC now owns 88,263 shares of the medical instruments supplier’s stock worth $692,000 after purchasing an additional 50,108 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in AngioDynamics by 20.6% during the fourth quarter. Nuveen Asset Management LLC now owns 430,429 shares of the medical instruments supplier’s stock worth $3,375,000 after purchasing an additional 73,397 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Trading Up 3.2 %

ANGO opened at $6.51 on Wednesday. The business’s 50 day moving average is $5.93 and its 200-day moving average is $6.46. The stock has a market cap of $260.79 million, a PE ratio of -1.35 and a beta of 0.66. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $11.38.

About AngioDynamics

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.